Effect of basic fibroblast growth factor, trafermin, on entero-related fistulae, report of two cases.

Abstract

Entero-related fistulae are often intractable. Recently, growth factors were generally in sight with the development of regenerative medicine. Basic fibroblast growth factor (bFGF) possesses potent angiogenic activity. In Japan, recombinant bFGF, also known as Trafermin, has been administered for intractable skin ulcer for its strong effect on tissue granulation. Here, we report the effect of bFGF for entero-related fistulae. Two intractable cases were treated by applying bFGF in the fistulae after performing the enterostomy. Case 1: Postoperative intractable vesicorectal fistula was treated by bFGF. 82 days later, fistula was closed. Case 2: Colonic perforation due to ischemic colitis was treated. 37 days after treatment, fistula was closed. In conclusion, in the treatment of the intractable entero-related fistulae, Trafermin was useful for healing the fistulae.

• Authors: Satoru Yamaguchi, Takayuki Asao, Junichi Nakamura, Kaori Tsuboi, Soichi Tsutsumi, Hiroyuki Kuwano
• Journal: Hepato-gastroenterology (Hepatogastroenterology) 2007 Apr-May Vol. 54 Issue 75 Pg. 803-5 ISSN: 0172-6390 [Print] Greece
• PMID: 17591067 (Publication Type: Case Reports, Journal Article)

Chemical References

• Peptide Fragments
• trafermin
• Fibroblast Growth Factors

Topics

• Aged
• Female
• Fibroblast Growth Factors (therapeutic use)
• Humans
• Intestinal Perforation (diagnostic imaging, drug therapy)
• Male
• Middle Aged
• Peptide Fragments (therapeutic use)
• Radiography
• Rectal Fistula (diagnostic imaging, drug therapy)
• Urinary Bladder (diagnostic imaging)